The C5a-C5aR axis is known to play an important role in complement-mediated thromboinflammation associated with a wide array of diseases (27, 30), and the monoclonal anti-C5 antibody eculizumab has been used clinically for many years to treat complement-driven diseases, such as paroxysmal nocturnal hemoglobinuria and atypical hemorrhagic uremic syndrome (31). This evidence concerns the gene C5AR1 and paroxysmal nocturnal hemoglobinuria.